Five Prime Therapeutics (NASDAQ: FPRX): Initiating Coverage With Buy Rating And First Price Target=$56

FPRX

Five Prime Therapeutics (FPRPX) is a San Francisco-based immunoncology company that is developing novel monoclonal antibodies for the treatment of various cancers. The company has been a focus of investor attention after signing a potential $1.74 billion deal to develop Cabiralizumab/FPA008 with ...

Five Prime Therapeutics (FPRPX) is a San Francisco-based immunoncology company that is developing novel monoclonal antibodies for the treatment of various cancers. The company has been a focus of investor attention after signing a potential $1.74 billion deal to develop Cabiralizumab/FPA008 with ...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics